Search Result

Results for "

human coronary arteries

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (1) Adrenergic Receptor (1) Apical Sodium-Dependent Bile Acid Transporter (1) Apoptosis (1) Arrestin (1) Cytochrome P450 (1) Endogenous Metabolite (1) Endothelin Receptor (4) Endothelin-Converting Enzyme (ECE) (2) Formyl Peptide Receptor (FPR) (1) HMG-CoA Reductase (HMGCR) (1) Interleukin Related (1) Leukotriene Receptor (1) PGE synthase (1) Phosphodiesterase (PDE) (1) PKA (1) Prostaglandin Receptor (3) Radionuclide-Drug Conjugates (RDCs) (1) Reference Standards (1)
By Research Areas:	Cancer (2) Cardiovascular Disease (15) Endocrinology (1) Inflammation/Immunology (4) Metabolic Disease (2) Neurological Disease (1)

By Targets:

5-HT Receptor (1)

Adrenergic Receptor (1)

Apical Sodium-Dependent Bile Acid Transporter (1)

Apoptosis (1)

Arrestin (1)

Cytochrome P450 (1)

Endogenous Metabolite (1)

Endothelin Receptor (4)

Endothelin-Converting Enzyme (ECE) (2)

Formyl Peptide Receptor (FPR) (1)

HMG-CoA Reductase (HMGCR) (1)

Interleukin Related (1)

Leukotriene Receptor (1)

PGE synthase (1)

Phosphodiesterase (PDE) (1)

PKA (1)

Prostaglandin Receptor (3)

Radionuclide-Drug Conjugates (RDCs) (1)

Reference Standards (1)

By Research Areas:

Cancer (2)

Cardiovascular Disease (15)

Endocrinology (1)

Inflammation/Immunology (4)

Metabolic Disease (2)

Neurological Disease (1)

Inhibitors & Agonists

Peptides

Natural
Products

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-104081

Cholestyramine 5+ Cited Publications Cholestyramine resin; Colestyramine	Apical Sodium-Dependent Bile Acid Transporter Cytochrome P450	Cardiovascular Disease Inflammation/Immunology
Cholestyramine (Cholestyramine resin) is an orally active bile acid sequestrant. Cholestyramine upregulates the expression of intestinal Apical sodium-dependent bile acid transporter and hepatic Cholesterol 7α-hydroxylase. Cholestyramine induces the expression of intestinal and hepatic cholesterol synthesis genes as well as hepatic lipogenesis genes, and promotes bile acid- and neutral sterol-mediated reverse cholesterol transport. Cholestyramine reduces intestinal cholesterol absorption and induces cholesterol efflux. Cholestyramine is applicable to research related to coronary artery disease, atherosclerotic cardiovascular disease and atherosclerosis .

HY-12717A

Phentolamine hydrochloride 5+ Cited Publications	Adrenergic Receptor	Cardiovascular Disease Endocrinology
Phentolamine hydrochloride is an orally active, selective α1 and α2 Adrenergic receptor antagonist. Phentolamine hydrochloride antagonizes the vasodilatory effect of Cromakalim (HY-110011) on isolated circumflex coronary artery segments in dogs. Phentolamine hydrochloride reduces systemic vascular resistance and increases cardiac output. Phentolamine hydrochloride improves erectile dysfunction. Phentolamine hydrochloride can be used for the research of erectile dysfunction .

HY-116326

BayCysLT2	Leukotriene Receptor	Inflammation/Immunology
BayCysLT2, an isophthalic acid derivative, is a selective and potent cysteinyl leukotriene 2 (CysLT2) receptor antagonist with an IC₅₀ value of 53 nM. BayCysLT2 inhibits calcium mobilization induced by leukotriene D4 in HEK293 cells expressing human CysLT2 receptors. BayCysLT2 reverses LTC4-induced increases in coronary artery perfusion pressure and decreases in contractility in isolated perfused guinea pig hearts .

HY-P3433

Sarafotoxin S6b	Endothelin Receptor	Cardiovascular Disease
Sarafotoxin S6b is a vasoconstrictor peptide, and a non-selective endothelin receptor agonist. Sarafotoxin S6b can induce contraction in isolated human coronary arteries , the K_i values of Coronary artery, Saphenous vein and Coronary artery are 0.27, 0.55 and 19.5 nM, respectively .

HY-E70559

Prostaglandin D synthase	PGE synthase	Cardiovascular Disease Cancer
Prostaglandin D synthase is a biomarker for meningioma cells and coronary artery disease. Lipocalin-type Prostaglandin D synthase (L-PGDS) is present in the atherosclerotic plaque of the human coronary artery and can be detectable in human serum .

HY-105082

Avitriptan BMS 180048	5-HT Receptor	Cardiovascular Disease Neurological Disease
Avitriptan is a 5-HT_1B/1D receptor agonist, with pK_is of 7.44 ( 5-HT_1B rat), 7.68 ( 5-HT_1B human) and 8.36 ( 5-HT_1D human). Avitriptan constricts the isolated coronary artery. Avitriptan can be used for migraines .

HY-106080A

Furegrelate sodium U-63557A	Prostaglandin Receptor	Cardiovascular Disease
Furegrelate Sodium (U-63557A) is a potent, orally available, and selective thromboxane synthase inhibitor. Furegrelate Sodium inhibits human platelet microsomal thromboxane A2 (TxA2) synthase with an IC₅₀ of 15 nM. Furegrelate Sodium is being developed as an antiplatelet agent .

HY-106080

Furegrelate U-63557A free acid	Prostaglandin Receptor	Cardiovascular Disease
Furegrelate (U-63557A free acid) is a potent, orally available, and selective thromboxane synthase inhibitor. Furegrelate inhibits human platelet microsomal thromboxane A2 (TxA2) synthase with an IC₅₀ of 15 nM. Furegrelate is being developed as an antiplatelet agent .

HY-106080AR

Furegrelate sodium (Standard) U-63557A (Standard)	Prostaglandin Receptor Reference Standards	Cardiovascular Disease
Furegrelate (sodium) (Standard) is the analytical standard of Furegrelate (sodium). This product is intended for research and analytical applications. Furegrelate Sodium (U-63557A) is a potent, orally available, and selective thromboxane synthase inhibitor. Furegrelate Sodium inhibits human platelet microsomal thromboxane A2 (TxA2) synthase with an IC50 of 15 nM. Furegrelate Sodium is being developed as an antiplatelet agent .

HY-14664D

Fluvastatin sodium monohydrate XU 62-320 monohydrate	HMG-CoA Reductase (HMGCR) Apoptosis	Cardiovascular Disease Cancer
Fluvastatin (XU 62-320) sodium monohydrate is a first fully synthetic, competitive HMG-CoA reductaseinhibitor with an IC₅₀ of 8 nM. Fluvastatin (sodium monohydrate) protects vascular smooth muscle cells against oxidative stress through the Nrf2-dependent antioxidant pathway .

HY-120148A

SM19712	Endothelin-Converting Enzyme (ECE) Endothelin Receptor	Cardiovascular Disease Metabolic Disease Inflammation/Immunology
SM19712 is an orally active, selective endothelin converting enzyme (ECE) inhibitor. SM19712 inhibits conversion of big ET-1 to ET-1. SM19712 attenuates colonic angiogenesis, tissue injury, inflammation, without altering colon shortening or myeloperoxidase levels in mice. SM19712 can be used for the research of inflammatory bowel disease (colitis), ischemic acute renal failure, acute myocardial infarction, and myocardial ischemia/reperfusion injury .

HY-120148

SM19712 free acid	Endothelin-Converting Enzyme (ECE) Endothelin Receptor	Cardiovascular Disease Metabolic Disease Inflammation/Immunology
SM19712 free acid is an orally active, selective endothelin converting enzyme (ECE) inhibitor. SM19712 free acid inhibits conversion of big ET-1 to ET-1. SM19712 free acid attenuates colonic angiogenesis, tissue injury, inflammation, without altering colon shortening or myeloperoxidase levels in mice. SM19712 free acid can be used for the research of inflammatory bowel disease (colitis), ischemic acute renal failure, acute myocardial infarction, and myocardial ischemia/reperfusion injury .

HY-N18868

1-Palmitoyl-2-capryloyl-sn-glycero-3-phosphocholine PC(16:0/8:0)	Endogenous Metabolite	Cardiovascular Disease
1-Palmitoyl-2-capryloyl-sn-glycero-3-phosphocholine (PC(16:0/8:0)) is a phosphatidylcholine glycerophospholipid. 1-Palmitoyl-2-capryloyl-sn-glycero-3-phosphocholine promotes platelet aggregation and flow-induced platelet-dependent thrombus formation. 1-Palmitoyl-2-capryloyl-sn-glycero-3-phosphocholine is a valid biomarker for CAD risk, severity, and subtype differentiation. 1-Palmitoyl-2-capryloyl-sn-glycero-3-phosphocholine is suitable for basic research on various types of coronary artery disease .

HY-181822

BMS-986331	Formyl Peptide Receptor (FPR) Arrestin PKA Interleukin Related	Cardiovascular Disease
BMS-986331 is an orally active selective N-Formyl Peptide Receptor 2 (FPR2) agonist with an EC₅₀ of 0.5 nM in humans and 1 nM in rats. BMS-986331 activates Gαi2, GαoA, Gα12, Gα13 signaling pathways, recruits β-arrestin1 and β-arrestin2, and inhibits downstream cAMP. BMS-986331 induces the expression and release of the pro-resolution cytokine IL-10. BMS-986331 improves cardiac structure and function in a rat model of heart failure induced by permanent coronary artery occlusion. BMS-986331 can be used for the research of heart failure .

HY-136785

PD151242	Endothelin Receptor Radionuclide-Drug Conjugates (RDCs)	Cardiovascular Disease
PD151242 is a selective competitive antagonist of the endothelin ET_A receptor, with K_D values of 0.65 nM, 0.64 nM and 1.92 nM for human, rat and porcine receptors, respectively, and a K_D value of 104 μM for the human ET_β receptor. When radiolabeled as [ ¹²⁵I]-PD151242, PD151242 can be used to visualize and localize renal vascular ET_A receptors .

HY-106830

Pelrinone	Phosphodiesterase (PDE)	Cardiovascular Disease
Pelrinone is an orally active cardiotonic agent and PDE III inhibitor with an IC₅₀ of 36 μM. Pelrinone elevates intracellular cAMP levels. The action of Pelrinone is independent of β-adrenergic receptors, and it does not inhibit Na ⁺/K ⁺-ATPase. Pelrinone exerts positive inotropic and vasodilatory effects. Pelrinone inhibits platelet aggregation, reduces thrombus formation, and exerts weak anticoagulant activity without altering hematocrit or circulating platelet counts. Pelrinone can be used in research related to congestive heart failure and coronary thrombosis .

Cat. No.	Product Name	Target	Research Area

HY-P3433

Sarafotoxin S6b	Endothelin Receptor	Cardiovascular Disease
Sarafotoxin S6b is a vasoconstrictor peptide, and a non-selective endothelin receptor agonist. Sarafotoxin S6b can induce contraction in isolated human coronary arteries , the K_i values of Coronary artery, Saphenous vein and Coronary artery are 0.27, 0.55 and 19.5 nM, respectively .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N18868

1-Palmitoyl-2-capryloyl-sn-glycero-3-phosphocholine PC(16:0/8:0)	Structural Classification Microorganisms Terpenoids Sesquiterpenes Lipid Source Classification	Endogenous Metabolite
1-Palmitoyl-2-capryloyl-sn-glycero-3-phosphocholine (PC(16:0/8:0)) is a phosphatidylcholine glycerophospholipid. 1-Palmitoyl-2-capryloyl-sn-glycero-3-phosphocholine promotes platelet aggregation and flow-induced platelet-dependent thrombus formation. 1-Palmitoyl-2-capryloyl-sn-glycero-3-phosphocholine is a valid biomarker for CAD risk, severity, and subtype differentiation. 1-Palmitoyl-2-capryloyl-sn-glycero-3-phosphocholine is suitable for basic research on various types of coronary artery disease .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks